Results 101 to 110 of about 8,474,282 (288)
Unlocking the potential of cell‐permeable nanobodies for intracellular applications
FEBS Letters, EarlyView.This review outlines current strategies for delivery of nanobodies into cells and highlights recent examples of functional applications. By addressing and manipulating intracellular targets, these molecules hold great potential for treating cancer, respiratory diseases and neurological disorders, making this a vibrant area of research in the biomedical Mariona Gené‐Verdés, Luise Franz, Christian P.R. Hackenberger +2 morewiley +1 more sourceThe presence of donor-specific human leukocyte antigen antibodies does not preclude successful withdrawal of tacrolimus in stable renal transplant recipients.
, 2007 Contains fulltext :
52624.pdf (Publisher’s version ) (Open Access)BACKGROUND: Because of the adverse events associated with the administration of immunosuppressive drugs, reduction of immunosuppression after solid-organ transplantation ...Berkel, Y. van, Allebes, W.A., Joosten, I., Kreijveld, E., Hilbrands, L.B. +4 morecore +1 more sourceDevelopmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley +13 morewiley +1 more sourceStimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi +19 morewiley +1 more sourceDonor‐Specific Antibodies in Pediatric Intestinal and Multivisceral Transplantation: The Role of Liver and Human Leukocyte Antigen Mismatching
, 2018 Rejection is one of the most important drawbacks for graft and patient survival in intestinal and multivisceral transplantation. However, there is no consensus on the diagnostic criteria for humoral rejection, and the literature about the role of donor ...Paloma Talayero, Esther Ramos Boluda, Francisco Hernández Oliveros, Ramos Boluda, Esther, Prieto Bozano, Gerardo, Estela Paz‐Artal, Gerardo Prieto Bozano, Hernández Oliveros, Francisco, Elena Gómez Massa, Mancebo Sierra, María Esther, Jorge Calvo Pulido, Castro Panete, María José, Talayero, Paloma, López Santamaría, Manuel, María José Castro Panete, Gómez Massa, Elena, Paz Artal, Estela Natividad, Manuel López Santamaría, Esther Mancebo, Calvo Pulido, Jorge +19 morecore +1 more sourceCharacterization of immunoglobulin G antibodies to Plasmodium falciparum sporozoite surface antigen MB2 in malaria exposed individuals [PDF]
, 2009 Background MB2 protein is a sporozoite surface antigen on the human malaria parasite Plasmodium falciparum. MB2 was identified by screening a P. falciparum sporozoite cDNA expression library using immune sera from a protected donor immunized via the ...James Anthony A, de la Vega, Patricia, John, Chandy C, Thanh V Nguyen, Nguyen, Thanh V, de la Vega, P, John B Sacci, Patricia de la Vega, James, Anthony A, Kang Angray S, John Chandy C, James, AA, Nguyen, T.V., Sacci, John B, Kang, A.S., Sacci John B, de la Vega, P., Nguyen Thanh V, Anthony A James, de la Vega Patricia, John, C.C., Kang, Angray S, Angray S Kang, Sacci, J.B., Patricia Vega, Chandy C John, John, CC, Nguyen, TV, Kang, AS, Jr, SJB, James, A.A. +30 morecore +1 more sourceSpatial and single‐nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers
Molecular Oncology, EarlyView.Matched spatial transcriptomics and single‐nuclei RNA‐seq were generated for anaplastic and BRAFV600E papillary thyroid cancers revealing generic and tumor‐specific states occurring in cancer cells and in the tumor microenvironment. In this context, cancer dedifferentiation mirrored organoid maturation through ordered thyroid marker gain/loss ...Adrien Tourneur, Joel Rodrigues Vitória, Manuel Saiselet, Ligia Craciun, Denis Larsimont, Anne Lefort, Frédérick Libert, Carine Maenhaut, Sabine Costagliola, Maxime Tarabichi, Mirian Romitti, Vincent Detours +11 morewiley +1 more sourceInhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli +10 morewiley +1 more sourceDifferential effects of donor-specific HLA antibodies in living versus deceased donor transplant [PDF]
, 2018 The presence of donor-specific anti-HLA antibodies (DSAs) is associated with increased risk of graft failure after kidney transplant. We hypothesized that DSAs against HLA class I, class II, or both classes indicate a different risk for graft loss ...Drop, A. C. A. D., E.M. van Duijnhoven, Lardy, N.M., Nurmohamed, SA, van der Pant, K A, Sanders, J. S.F., Drop, A, van Ittersum, FJ, Seelen, M. A. J., van der Weerd, N C, J.S.F. Sanders, van der Weerd, NC, Roelen, D L, Plaisier, L., Bots, M. L., Boog, P.J.M. van der, Tilanus, M. G.J., J.W. de Fijter, van der Weerd, N. C., Hilbrands, L B, Bots, M L, Hepkema, B.G., Claas, F H, Betjes, M. G.H., Christiaans, M. H. L., Gelens, M, van Zuilen, A. D., Hilbrands, L.B., Wisse, B.W., Lambeck, A. J.A., Voorter, C. E., Hoitsma, A., A.D. van Zuilen, Heidt, S, Spierings, E., Tilanus, M. G. J., M.H.L. Christiaans, Nurmohamed, S.A., Verhaar, M. C., A. van der Meer, S. Heidt, Joosten, I., Hepkema, B G, Lambeck, A J, Seelen, M.A.J., Hepkema, BG, Allebes, W. A., Hack, C. E., L.B. Hilbrands, van der Boog, P J M, Baas, M.C., N.C. van der Weerd, Nurmohamed, S A, Sanders, J S F; id_orcid, Lardy, NM, Verhaar, M C, S.A. Nurmohamed, van Zuilen, A D, Heidt, S; id_orcid, Meer, A. van der, van der Boog, P. J.M., Otten, HG, Seelen, M A J, Allebes, W.A., Bungener, L.B., Verhaar, M.C., Wieten, L, Verhaar, MC, M.G.J. Tilanus, N.M. Lardy, Ten Berge, I J M, H.G. Otten, F.J. Bemelman, Hack, C E, Bungener, L. B., van der Meer, A, E.G. Kamburova, M. Gelens, Swelsen, W., van Reekum, F. E., M.L. Bots, Lambeck, A.J.A., F.E. van Reekum, Zuilen, A.D. van, Kamburova, E. G., van Ittersum, F. J., B.W. Wisse, Otten, H. G., Seelen, M. A.J., Baas, M C, Christiaans, MHL, Allebes, WA, Hack, CE, Roozendaal, C, Hepkema, B. G., Kamburova, E.G., I. Joosten, Weerd, N.C. van der, K.A. van der Pant, M.C. Verhaar, Otten, H.G., Sanders, J.S.F., ten Berge, IJM, van der Boog, P. J. M., L.B. Bungener, M.A.J. Seelen, Tilanus, MGJ, Lambeck, AJA, Bemelman, F J, van Ittersum, F J, Drop, A.C.A.D., Nurmohamed, S. A., Kamburova, E G, Bemelman, FJ, C.E. Hack, Roelen, D. L., Duijnhoven, E.M. van, Bemelman, F. J., Fijter, J.W. de, Betjes, M. G. H., Roozendaal, C., Lardy, N. M., Plaisier, L, M.G.H. Betjes, van Reekum, F E, W. Swelsen, Otten, H G, Baas, M. C., Tilanus, M G J, de Fijter, J W, van der Meer, A., ten Berge, I. J.M., Pant, K.A. van der, M.C. Baas, de Fijter, J. W., Sanders, J S F, Roelen, DL, P.J.M. van der Boog, Sanders, J. S. F., Bungener, L B, A. Hoitsma, L. Plaisier, Berge, I.J.M. ten, Allebes, W A, A.J.A. Lambeck, Claas, FH, Hilbrands, LB, D.L. Roelen, Christiaans, M H L, Wisse, B W, C. Roozendaal, ten Berge, I. J. M., W.A. Allebes, Bots, ML, van Duijnhoven, E. M., Sanders, JSF, Spierings, E, Betjes, M G H, F.H. Claas, Heidt, S., Tilanus, M.G.J., Bungener, LB, Lardy, N M, Meer, A, B.G. Hepkema, Gelens, M., Christiaans, M.H.L., Seelen, MAJ, Voorter, C E, Wisse, B. W., E. Spierings, Lambeck, A. J. A., van Duijnhoven, E M, Betjes, M.G.H., Hilbrands, L. B., Drop, A. C.A.D., Bemelman, F.J., Christiaans, M. H.L., I.J.M. ten Berge, van Zuilen, AD, Joosten, I, Roelen, D.L., Wieten, L., Bots, M.L., Voorter, C.E., Hoitsma, A, Hack, C.E., Claas, F.H., A.C.A.D. Drop, Voorter, CE, de Fijter, JW, Swelsen, W, Drop, A C A D, Reekum, F.E. van, F.J. van Ittersum, Ittersum, F.J. van, L. Wieten, van der Pant, K. A., C.E. Voorter, Claas, F. H., MS Nefrologie, Regenerative Medicine and Stem Cells, MS Mondziekten/Kaakchirurgie, Circulatory Health, CTI Otten, Nefro Vasculaire Geneeskunde, Cardiovasculaire Epi Team 5, CDL Celdiagnostiek, Infection & Immunity, JC onderzoeksprogramma Cardiovascular Health, CTI +210 morecore +1 more source
